Amgen, Inc. (AMGN) Stock Price Today
Aura AI Summary
Key Stats
- $247.70BMarket Cap
- 2,033,159Volume
- HealthSector
- $478.4852W High
- $313.8552W Low
- 73 DaysTypical Hold Time
- $288.52BEnterprise Value
- 2.2%Div Yield
- 66% Sell | 34% BuyTrading Activity
Track Amgen, Inc. (AMGN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Amgen, Inc. has traded between a low of $313.85 and a high of $478.48, highlighting its annual price range. Buy and sell Amgen, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Most Recent News
Opendoor shares rise 7.63% on new FSBO.com deal and insider buying amid housing market challenges
Opendoor Technologies' stock rose 7.63% to $1.27 following a new partnership with FSBO.com and insider buying by a company director, signaling potential recovery. Despite a 12% sales increase to $1 billion in Q3, net losses widened to $218 million, r...

Invesco QQQ Trust dips 14% from record but could rise 36% by 2030 on earnings growth.
The Invesco QQQ Trust, tracking the Nasdaq-100, hit a record $759.66 in October but has since fallen about 14% to around $654. Despite this drop, it remains up 6% for 2026. The fund's future looks promising with an expected rise to $890 by 2030, driv...

Pershing Square swaps Microsoft shares for options, keeping its bet steady despite reported share sales.
Pershing Square reduced its Microsoft shares by about 2.1 million last quarter but bought 2 million deep-in-the-money options on Microsoft, keeping its overall exposure roughly the same. The options strategy allows the fund to maintain a bullish stan...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.